Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharma (TKPYY)

Takeda Pharma (TKPYY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,919,552
  • Shares Outstanding, K 1,562,360
  • Annual Sales, $ 15,935 M
  • Annual Income, $ 1,682 M
  • 60-Month Beta 0.42
  • Price/Sales 1.64
  • Price/Cash Flow N/A
  • Price/Book 1.36
  • Price/Earnings ttm 12.22
  • Earnings Per Share ttm 1.37
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/07/19
  • Annual Dividend & Yield 0.58 (3.48%)
  • Most Recent Dividend 0.288 on 09/27/18
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.5000 +7.03%
on 12/18/18
19.2300 -13.73%
on 11/26/18
-2.6300 (-13.68%)
since 11/21/18
3-Month
15.5000 +7.03%
on 12/18/18
21.9399 -24.38%
on 09/26/18
-4.3650 (-20.83%)
since 09/21/18
52-Week
15.5000 +7.03%
on 12/18/18
31.2900 -46.98%
on 02/01/18
-11.8100 (-41.58%)
since 12/21/17

Most Recent Stories

More News
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

--a^' Sustained innovation beyond 2024 based on a promising early stage pipeline and novel research platforms intended to provide transformative benefit for targeted populations with high unmet needs

TKPYY : 16.5900 (-0.90%)
New Analyses from the Phase 3 HELP Study(TM) Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO(R) (lanadelumab-flyo) Injection During Extended Study Treatment Period

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO(R) (lanadelumab-flyo) injection in...

TKPYY : 16.5900 (-0.90%)
Phase 3 Trial of NINLARO(TM) (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

--- Data to be Submitted for Presentation at an Upcoming Medical Meeting -

TKPYY : 16.5900 (-0.90%)
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American Society of Hematology (ASH) Annual Meeting...

TKPYY : 16.5900 (-0.90%)
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

--a^' Potential to be the First CAR Cell Therapy Approved for Outpatient Administration

TKPYY : 16.5900 (-0.90%)
Takeda Continues Strategic Divestitures With Sale of Select OTC and Non-Core Assets to STADA for $660 Million USD

--Strengthens alignment of Growth & Emerging Markets Business Unit portfolio with Takeda's global business areas

STDAF : 86.2100 (-3.11%)
TKPYY : 16.5900 (-0.90%)
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

TKPYY : 16.5900 (-0.90%)
TAK : 20.64 (-0.91%)
Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

--a^' Takeda acquires exclusive global license to investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease

TKPYY : 16.5900 (-0.90%)
Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naive Patients with Ulcerative Colitis or Crohn's Disease

--

TKPYY : 16.5900 (-0.90%)
Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

--Agreement simplifies portfolio in Takeda's NEMEA region

TKPYY : 16.5900 (-0.90%)
Trade TKPYY with:

Key Turning Points

2nd Resistance Point 17.1900
1st Resistance Point 16.8900
Last Price 16.5900
1st Support Level 16.3200
2nd Support Level 16.0500

See More

52-Week High 31.2900
Fibonacci 61.8% 25.2582
Fibonacci 50% 23.3950
Fibonacci 38.2% 21.5318
Last Price 16.5900
52-Week Low 15.5000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar